These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 35118240)
41. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Najima Y; Tomizawa-Murasawa M; Saito Y; Watanabe T; Ono R; Ochi T; Suzuki N; Fujiwara H; Ohara O; Shultz LD; Yasukawa M; Ishikawa F Blood; 2016 Feb; 127(6):722-34. PubMed ID: 26702062 [TBL] [Abstract][Full Text] [Related]
42. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755 [TBL] [Abstract][Full Text] [Related]
44. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577 [TBL] [Abstract][Full Text] [Related]
45. [WT1-targeting cancer vaccine]. Sugiyama H Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381 [TBL] [Abstract][Full Text] [Related]
46. WT1 peptide immunotherapy for cancer in children and young adults. Hashii Y; Sato E; Ohta H; Oka Y; Sugiyama H; Ozono K Pediatr Blood Cancer; 2010 Aug; 55(2):352-5. PubMed ID: 20582983 [TBL] [Abstract][Full Text] [Related]
47. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465 [TBL] [Abstract][Full Text] [Related]
48. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Dao T; Korontsvit T; Zakhaleva V; Jarvis C; Mondello P; Oh C; Scheinberg DA Oncoimmunology; 2017; 6(2):e1252895. PubMed ID: 28344864 [TBL] [Abstract][Full Text] [Related]
53. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers]. Kato Y Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951 [TBL] [Abstract][Full Text] [Related]
54. Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions. Luo P; Jing W; Yi K; Wu S; Zhou F Leuk Lymphoma; 2020 Sep; 61(9):2059-2067. PubMed ID: 32401109 [TBL] [Abstract][Full Text] [Related]
55. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Ariyaratana S; Loeb DM Expert Rev Mol Med; 2007 May; 9(14):1-17. PubMed ID: 17524167 [TBL] [Abstract][Full Text] [Related]
56. WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction. Oka Y; Tsuboi A; Shirakata T; Hosen N; Nishida S; Oji Y; Sugiyama H Rinsho Ketsueki; 2009 May; 50(5):352-7. PubMed ID: 19483394 [No Abstract] [Full Text] [Related]
57. Development of lymphopoiesis as a function of the thymic microenvironment. Use of CD8+ cytotoxic T lymphocytes for cellular immunotherapy of human cancer. Bodey B In Vivo; 1994; 8(5):915-43. PubMed ID: 7727741 [TBL] [Abstract][Full Text] [Related]
58. Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases. Jiang Y; Lv X; Ge X; Qu H; Zhang Q; Lu K; Lu Y; Xue C; Zhang L; Wang X Int Immunopharmacol; 2021 May; 94():107504. PubMed ID: 33657524 [TBL] [Abstract][Full Text] [Related]
59. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157 [TBL] [Abstract][Full Text] [Related]
60. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Ohminami H; Yasukawa M; Fujita S Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]